Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2008 1
2011 2
2012 1
2013 2
2014 3
2015 1
2016 6
2017 6
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
Watermann C, Pasternack H, Idel C, Ribbat-Idel J, Brägelmann J, Kuppler P, Offermann A, Jonigk D, Kühnel MP, Schröck A, Dreyer E, Rosero C, Nathansen J, Dubrovska A, Tharun L, Kirfel J, Wollenberg B, Perner S, Krupar R. Watermann C, et al. Among authors: schrock a. Clin Cancer Res. 2021 Jan 15;27(2):632-644. doi: 10.1158/1078-0432.CCR-20-0197. Epub 2020 Oct 27. Clin Cancer Res. 2021. PMID: 33109740
PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.
Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, Golletz C, Brossart P, Bootz F, Landsberg J, Kristiansen G, Dietrich D. Franzen A, et al. Among authors: schrock a. Oncotarget. 2017 Dec 7;9(1):641-650. doi: 10.18632/oncotarget.23080. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416641 Free PMC article.
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Müller T, Braun M, Dietrich D, Aktekin S, Höft S, Kristiansen G, Göke F, Schröck A, Brägelmann J, Held SAE, Bootz F, Brossart P. Müller T, et al. Among authors: schrock a. Oncotarget. 2017 May 2;8(32):52889-52900. doi: 10.18632/oncotarget.17547. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881780 Free PMC article.
Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
Schröck A, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D. Schröck A, et al. Clin Chem. 2017 Jul;63(7):1288-1296. doi: 10.1373/clinchem.2016.270207. Epub 2017 May 17. Clin Chem. 2017. PMID: 28515105
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.
Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S. Laban S, et al. Among authors: schrock a. Oncotarget. 2017 Feb 28;8(9):14719-14735. doi: 10.18632/oncotarget.14830. Oncotarget. 2017. PMID: 28146422 Free PMC article.
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S. von Mässenhausen A, et al. Among authors: schrock a. Int J Mol Sci. 2016 Dec 22;18(1):7. doi: 10.3390/ijms18010007. Int J Mol Sci. 2016. PMID: 28025482 Free PMC article.
24 results